Scarica l'app Stockscreener
19.08
0.63%
0.12
Dopo l'orario di chiusura:
19.08
Precedente Chiudi:
$18.96
Aprire:
$18.85
Volume 24 ore:
102.60K
Relative Volume:
0.35
Capitalizzazione di mercato:
$621.66M
Reddito:
-
Utile/perdita netta:
$-29.59M
Rapporto P/E:
-14.96
EPS:
-1.275
Flusso di cassa netto:
$-18.35M
1 W Prestazione:
+1.09%
1M Prestazione:
-0.31%
6M Prestazione:
+113.90%
1 anno Prestazione:
+196.73%
Intervallo 1D:
$18.51
$19.32
Intervallo di 1 settimana:
$18.51
$20.30
Portata 52W:
$5.55
$29.27
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Nome
Nuvectis Pharma Inc
Settore
Industria
Telefono
360-837-7232
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
19.08 | 617.75M | 0 | -29.59M | -18.35M | -1.275 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Iniziato | Maxim Group | Buy |
| 2025-03-17 | Iniziato | Laidlaw | Buy |
| 2022-07-13 | Iniziato | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Behavioral Patterns of NVCT and Institutional Flows - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap UpWhat's Next? - MarketBeat
Certain Common Stock of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Nuvectis Pharma (NVCT) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market Wi - The National Law Review
Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next - TipRanks
Soleus group (NVCT) discloses 1.65M-share, 5.1% Nuvectis Pharma stake - Stock Titan
HC Wainwright Boosts Earnings Estimates for Nuvectis Pharma - MarketBeat
(NVCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Lucid Capital Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Nuvectis Pharma’s Heavy Reliance on Haisco Poses Major Operational and Geopolitical Risks - TipRanks
Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Down After Earnings Miss - MarketBeat
Nuvectis Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Nuvectis Pharma, Inc. 2Q 2026: Net loss $(7.02)M, EPS $(0.30) — 10-Q Summary - TradingView
NVCT: Q2 2026 net loss widened to $7.0M; $106.3M raised in July extends cash runway for clinical development - TradingView
Nuvectis Pharma (NASDAQ: NVCT) boosts cash with $115M stock sale and new drug licenses - Stock Titan
Nuvectis Reports $7.0 Million Q2 Net Loss After Pipeline Deals - Quiver Quantitative
NVCT: Secured $115M financing, advanced late-stage pipeline, and reported higher R&D-driven net loss - TradingView
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
NVCT Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - Yahoo Finance
Nuvectis Pharma (NVCT) Expected to Announce Earnings on Tuesday - MarketBeat
Nuvectis Pharma Inc (NVCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NVCT|Nuvectis Pharma Inc|Price:19.530|Chg%:+0.220 - TradingKey
NVCT|Nuvectis Pharma Inc|Price:19.310|Chg%:-0.840 - TradingKey
Nuvectis Pharma Inc (NVCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nuvectis Pharma Inc (NVCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nuvectis Pharma Inc (NVCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvectis Pharma Inc (NVCT) Cash Flow - TradingKey
Nuvectis Pharma Inc (NVCT) Income Statement - TradingKey
Maxim Group Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $39 - Moomoo
China approves Nuvectis’ ciprocopan for blood disorder PNH - Investing.com UK
Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39 - TipRanks
Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor - TipRanks
Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor - Benzinga
Correction: Nuvectis Announces Marketing Approval of Ciprocopan in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors - Investing News Network
Nuvectis Pharma Announces First Global Approval of Once-Daily Oral Complement Factor B Inhibitor Ciprocopan in China for PNH - Quiver Quantitative
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors - GlobeNewswire
China approves ciprocopan, first oral once-dail... - Pluang
China approves Nuvectis’ ciprocopan for blood disorder PNH By Investing.com - Investing.com Australia
Nuvectis Pharma receives China approval for Ciprocopan to treat PNH in patients not given complement inhibitors - Traders Union
Nuvectis Drug Reached 12 g/dL in 59.5% of PNH Patients - Stock Titan
Nuvectis' NXP100 Just Achieved The First Marketing Approval Ever For A Once-Daily Oral Factor B Inhibitor - Menafn
NVCT Q1 2026 Earnings: EPS Beat Estimates as Company Advances PipelineEarnings Yield Analysis - dars.gov.et
Nuvectis Pharma Prices $100 Million Public Offering to Advance Pipeline - citybuzz -
Nuvectis Pharma Targets a $9.8 Billion Oral PNH Market With Late-Stage NXP100 - t.co
Wall Street analysts see a 61.46% upside in Nuvectis Pharma (NVCT): Can the stock really move this high? - MSN
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nuvectis Pharma Inc Azioni (NVCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
Jun 30 '26 |
Buy |
20.00 |
12,500 |
250,000 |
3,688,424 |
| BENTSUR RON | Chairman & CEO |
Nov 05 '25 |
Buy |
5.72 |
5,000 |
28,600 |
3,525,924 |
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):